

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
300 Corporate Center Drive, Suite 600, Camp Hill, PA 17011

Wednesday, July 13, 2022 – 12:00 PM – 1:30 PM

- Present:** Meghan McNelly, PharmD, Jill Schaeffer, RN,
Dr. Mahmood Usman, Debbie Rose (Participant Advisory), Michelle Bennett, RPh, Dr. Keith Brown, Dr. Christopher Hughes,
Dr. Carla Huitt, Dr. Kolin Good
- Absent:** Dr. Venkateswara Davuluri
- Non-Voting Members:** Amy Nowacki (Pharmacy), Jason Skaria (Pharmacy Manager), Shalyn Kline (Pharmacy), Marci Kramer (QI Director),
Evan Sebastian (Pharmacy), Tanayja Sams (Pharmacy), Rhonda Hredzak (Pharmacy), George Kimbrow (Clinical Policy
Coodinator), Tanika Taylor (G&A Director).
- Call to Order:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:02 PM.
- Adjourned:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:19 PM.
- Next Meeting:** Wednesday, October 12, 2022 – 12:00 PM
- Submitted By:** Shalyn Kline (PHW Pharmacy)

Shalyn Kline, PharmD

Date: 10/12/2022

Committee Chair: _____

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Meghan McNelly called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:02 PM.	Meeting Called to Order		Meghan McNelly
A. Introductions	No new introductions			Meghan McNelly
B. Announcements	<p>Departure of Pharmacist team member announced. Meghan asked for a recommendation for replacement from the team.</p> <p>Meghan reminded all that 75% attendance is required for all voting members to remain as active committee members.</p> <p>Every month, a report is sent to the state. The state provides feedback, and the necessary follow-up is completed.</p>	Recommendation for new pharmacist team member requested from team.		Meghan McNelly
C. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> i. Voting and vote totals ii. Tie breaker iii. Pennsylvania's Review and Approval Process 	No action required or taken.		Meghan McNelly
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Meghan McNelly
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q2_2022. No objections were made.	Adoption of Q2_2022 Meeting Minutes recorded as approved		Shalyn Kline
III. Old Business	Meghan addressed Debbie's concern regarding language of Prior Authorization denial letters brought up in Q2 P&T meeting. Denial			Meghan McNelly

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	letters are sent in English, but there is instruction provided in each language of how to access in the letter in their preferred language.			
A. Policy Submission Status	There are no outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline
IV. New Business				
A. Statewide PDL updates	According to the CHC contract, a compliance rate of 95 percent is expected. The compliance rate is currently being audited internally. The Pennsylvania Department of Human Services is conducting an audit of prior authorization determination data.			Shalyn Kline
B. GERD/PPI	A vote was taken for the approval of the GERD/PPI provider education. No objections were made.	The provider education was Committee approved.		Shalyn Kline
C. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Shalyn Kline
D. Guidelines – Drug Coverage Criteria	Review on Combined Summary Table for summary revisions, new policies created, and policies being replaced/retired for all lines of business.	The policy revisions were Committee approved.		Shalyn Kline
E. Complaints and Grievances Review	Shalyn stated that there were 4 determinations upheld and twenty overturned. Twelve of the twenty seven determinations were for opioids. There are 3 others not counted that are still in the pre-grievance and will be reported on next P&T. Discussion: Meghan advised that opioids are highest amount of Prior Authorizations due to restrictive access that correlated with the			Shalyn Kline/Meghan McNelly/Debbie Rose

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

	<p>State’s guidelines, and there were no findings of inappropriate determinations in relation to opioids.</p> <p>Debbie asked if data was present for the evaluation of age based opioid use due to personal experience with addiction in the advanced age population. Meghan advised that an age-based breakout was not currently an evaluation method and that no trends have been identified.</p>			
<p>F. Drug Utilization Review</p>	<p>Shalyn presented the drug utilization review, noted the numbers are only for the first 2 months of the quarter. Last month will be reported during the next P&T.</p> <p>FWA – There were 42 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. No issues were found. No Participants were identified with three or more practices/hospitals prescribing opioids.</p> <p>Inappropriate prescribing – 28 Participants were identified potentially using inappropriate antipsychotic medications. A fax is to be sent to providers for awareness.</p> <p>Disease management – There were 5 identified long-acting beta-agonist monotherapy. All were reviewed. 51 participants were identified for SABA overuse. Both populations will have a fax sent to providers for awareness.</p>			<p>Shalyn Kline</p>
<p>G. PBM Oversight</p>	<p>In Q2, there were 1,769 requests audited. (1,643 approvals, 126 denials).</p> <p>Corrective Action Plan put in place in Quarter 2 by PA DHS. Internal audit of all Prior Authorizations required by PHW pharmacists including PDL application, correct policy use, correct member/provider letter template, and decision timeline.</p>			<p>Jason Skaria/ Meghan McNelly</p>

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).

	Meghan stated that there is an ongoing 100% review of all Prior Authorizations by both Centene Pharmacy Services and internal PHW pharmacist, per the Corrective Action Plan. The continual trend down in rate for errors found month over month.			
K. Open Forum	<p>Meghan advised the P&T team is still seeking a participant member/family member for attendance.</p> <p>Dr. Hughes recommended reaching out to Case Managers for assistance in finding a participant/family member.</p>	PHW will continue to seek out participant for membership		Meghan McNelly
Adjournment	The meeting was adjourned at 12:19 pm	Meeting adjourned		Meghan McNelly

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).